Your browser doesn't support javascript.
loading
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Guo, Christina; Chénard-Poirier, Maxime; Roda, Desamparados; de Miguel, Maria; Harris, Samuel J; Candilejo, Irene Moreno; Sriskandarajah, Priya; Xu, Wen; Scaranti, Mariana; Constantinidou, Anastasia; King, Jenny; Parmar, Mona; Turner, Alison J; Carreira, Suzanne; Riisnaes, Ruth; Finneran, Laura; Hall, Emma; Ishikawa, Yuji; Nakai, Kiyohiko; Tunariu, Nina; Basu, Bristi; Kaiser, Martin; Lopez, Juanita Suzanne; Minchom, Anna; de Bono, Johann S; Banerji, Udai.
Afiliação
  • Guo C; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Chénard-Poirier M; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Roda D; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • de Miguel M; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Harris SJ; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Candilejo IM; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Sriskandarajah P; Division of Cancer Therapeutics, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Xu W; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Scaranti M; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Constantinidou A; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • King J; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Parmar M; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Turner AJ; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Carreira S; Cancer Biomarkers, The Institute of Cancer Research, London, UK.
  • Riisnaes R; Cancer Biomarkers, The Institute of Cancer Research, London, UK.
  • Finneran L; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
  • Hall E; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
  • Ishikawa Y; Translational Research Division, Chugai Pharmaceutical, Tokyo, Japan.
  • Nakai K; Translational Research Division, Chugai Pharmaceutical, Tokyo, Japan.
  • Tunariu N; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Basu B; Department of Oncology, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Kaiser M; Division of Molecular Pathology and Myeloma Molecular Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Lopez JS; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Minchom A; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • de Bono JS; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.
  • Banerji U; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. Electronic address: udai.banerji@icr.ac.uk.
Lancet Oncol ; 21(11): 1478-1488, 2020 11.
Article em En | MEDLINE | ID: mdl-33128873
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cumarínicos / Inibidores de Proteínas Quinases / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Mieloma Múltiplo Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cumarínicos / Inibidores de Proteínas Quinases / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Mieloma Múltiplo Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido